Teladoc Health, Inc. (NYSE:TDOC) Position Raised by Himension Capital Singapore PTE. LTD.

Himension Capital Singapore PTE. LTD. boosted its position in Teladoc Health, Inc. (NYSE:TDOC) by 244.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 205,941 shares of the health services provider’s stock after purchasing an additional 146,131 shares during the quarter. Himension Capital Singapore PTE. LTD.’s holdings in Teladoc Health were worth $1,872,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. MetLife Investment Management LLC lifted its position in shares of Teladoc Health by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 98,504 shares of the health services provider’s stock valued at $904,000 after acquiring an additional 55,503 shares during the last quarter. Centiva Capital LP acquired a new position in shares of Teladoc Health in the 3rd quarter valued at $288,000. Quantinno Capital Management LP increased its stake in Teladoc Health by 190.4% in the 3rd quarter. Quantinno Capital Management LP now owns 186,143 shares of the health services provider’s stock worth $1,709,000 after purchasing an additional 122,050 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Teladoc Health in the 3rd quarter worth about $152,000. Finally, Geode Capital Management LLC raised its holdings in Teladoc Health by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 3,925,167 shares of the health services provider’s stock worth $36,042,000 after buying an additional 56,864 shares during the period. 76.82% of the stock is owned by institutional investors.

Teladoc Health Price Performance

NYSE TDOC opened at $7.26 on Friday. The company has a market cap of $1.26 billion, a P/E ratio of -1.26 and a beta of 1.73. The company has a fifty day simple moving average of $10.14 and a 200 day simple moving average of $9.77. Teladoc Health, Inc. has a 1 year low of $6.76 and a 1 year high of $15.21. The company has a current ratio of 1.73, a quick ratio of 1.69 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, February 26th. The health services provider reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.07). Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The business had revenue of $640.49 million for the quarter, compared to analyst estimates of $639.44 million. On average, sell-side analysts predict that Teladoc Health, Inc. will post -1.16 EPS for the current year.

Insider Buying and Selling at Teladoc Health

In other news, insider Adam C. Vandervoort sold 11,011 shares of Teladoc Health stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $8.42, for a total transaction of $92,712.62. Following the sale, the insider now owns 64,308 shares of the company’s stock, valued at approximately $541,473.36. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.95% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on TDOC shares. Royal Bank of Canada raised their target price on shares of Teladoc Health from $11.00 to $12.00 and gave the stock an “outperform” rating in a report on Friday, January 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research note on Thursday, February 27th. The Goldman Sachs Group cut their target price on shares of Teladoc Health from $16.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Bank of America raised their target price on Teladoc Health from $11.50 to $13.50 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Oppenheimer dropped their price target on Teladoc Health from $14.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, January 24th. Eleven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $11.26.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.